Tag Archives: CVS Specialty

GBT’s Oxbryta® Accepted by FDA for Priority Review for Pediatric Sickle Cell Disease

The FDA has accepted for Priority Review the supplemental New Drug Application (sNDA) for voxelotor (Oxbryta®) for the treatment of sickle cell disease in patients aged 4 to 11 years

JNJ’s UPTRAVI (selexipag) Receives FDA Approval for Intravenous Use in Adults

The FDA approved UPTRAVI® (selexipag) injection for intravenous (IV) use for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients with WHO functional class (FC) II–III, who are temporarily unable to take oral therapy

NUZYRA Continues to be the Primary Driver for Paratek Pharmaceuticals’ Growth

The FDA approved Paratek’s supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA® for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP)

Large Insurers Implementing White Bagging Policies

Large insurers are implementing policies requiring health care providers to get provider-administered therapies from specialty pharmacies